Patents Assigned to Senju Pharmaceuticals Co., Ltd.
-
Patent number: 10052411Abstract: The present invention provides a graft more suitable for the transplantation of corneal endothelial cells and an application method thereof. Specifically, the present invention provides a corneal endothelial preparation capable of cell proliferation in vivo, which contains a substrate and a corneal endothelial cell layer cultured on the substrate, and a treatment method of a disease selected from the group consisting of bullous keratopathy, corneal edema, corneal leukoma and corneal endothelial inflammation, which includes a step of transplanting the preparation to patients. As the substrate, collagen is used.Type: GrantFiled: January 18, 2007Date of Patent: August 21, 2018Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko Koizumi, Shigeru Kinoshita, Yuji Sakamoto
-
Publication number: 20180228901Abstract: The present invention provides a stable and clear aqueous liquid preparation containing (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl) oxyacetic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and bensalkonium chloride represented by the formula: [C6H5CH2N(CH3)2R]Cl wherein R is an alkyl group having 8-18 carbon atoms.Type: ApplicationFiled: April 16, 2018Publication date: August 16, 2018Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yuko SHIKAMURA, Yuka HIGASHIMURA
-
Publication number: 20180177766Abstract: Provided are a novel pharmaceutical use of PPAR? agonist such as a therapeutic agent for neurotrophic keratopathy, an improving agent for decrease of corneal sensitivity and the like, each containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: June 9, 2016Publication date: June 28, 2018Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shinya KOBAYASHI, Yoshikuni NAKAMURA, Takeshi TARUI, Tomoyuki WADA
-
Publication number: 20180140548Abstract: The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.Type: ApplicationFiled: January 18, 2018Publication date: May 24, 2018Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventor: Shirou SAWA
-
Patent number: 9968679Abstract: The present invention provides a stable and clear aqueous liquid preparation containing (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and benzalkonium chloride represented by the formula: [C6H5CH2N(CH3)2R]Cl wherein R is an alkyl group having 8-18 carbon atoms.Type: GrantFiled: January 30, 2014Date of Patent: May 15, 2018Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yuko Shikamura, Yuka Higashimura
-
Patent number: 9962289Abstract: Provided is a fragmentation tip, an intraocular surgery device, a method for suppressing an occurrence of cavitation, and a cataract surgery method, which can suppress the occurrence of cavitation. The fragmentation tip, which is attached to an intraocular surgery device configured to apply ultrasonic vibration, includes: a cylindrical support portion configured to be mounted on the intraocular surgery device; and a cylindrical tip body provided at a distal end of the support portion to be in communication with an internal space of the support portion, wherein the tip body has a cross sectional shape having a length in a first direction that is larger than a length in a second direction that is orthogonal to the first direction, and vibration is applied to the support portion so that the tip body rotates back and forth about an axis of the tip body that passes through its center in the first and second directions.Type: GrantFiled: April 18, 2012Date of Patent: May 8, 2018Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Makoto Kishimoto
-
Publication number: 20180105563Abstract: An object of the invention is to provide an agent for preventing or treating corneal disorders, such as corneal epithelial disorder, dry eye, and reduction in corneal sensitivity. This object is achieved by using angiopoietin-like protein 7 as an active ingredient.Type: ApplicationFiled: April 15, 2016Publication date: April 19, 2018Applicants: The University of Tokyo, Senju Pharmaceutical Co., Ltd.Inventors: Tomohiko USUI, Chiho YABUTA
-
Patent number: 9921419Abstract: The object of the present invention is to provide an annular device superior to a conventional annular device in the stability over an eyeball when being worn, which overcomes problems caused by wearing a conventional annular device. The above object is attained by preparing an annular device to be worn over the surface of the sclera, the annular device including an opening exposing the cornea and one or a plurality of approximately encircling grooves on an intermediate part between an inner rim part and an outer rim part. The annular device has a maximum thickness preferably in the intermediate part.Type: GrantFiled: May 29, 2014Date of Patent: March 20, 2018Assignees: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTDInventors: Akira Nakamura, Tsutomu Fukushima
-
Patent number: 9907750Abstract: The purpose of the present invention is to provide a technique for formulating a two-layer separation-type ophthalmic solution in which, during storage, an aqueous layer and an oil-containing layer containing squalane are separated from each other, wherein it is possible to homogeneously disperse the oil-containing layer in the aqueous layer while suppressing foaming by shaking the ophthalmic solution before administration, and the homogeneous dispersed state is maintained in a stable manner at least until administration. A two-layer separation-type ophthalmic solution containing squalane and water, wherein hyaluronic acid and/or a salt thereof and polyvinyl alcohol are contained in the ophthalmic solution and the polyvinyl alcohol content is set to 0.025 to 0.Type: GrantFiled: March 18, 2014Date of Patent: March 6, 2018Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Shirou Sawa
-
Publication number: 20180028667Abstract: Provided are an aqueous liquid preparation showing improved stability of N-[5-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-b]pyridazin-6-yl}oxy)-2-methylphenyl]-1,3-dimethyl-1H-pyrazole-5-carboxamide or a salt thereof in the aqueous liquid preparation, a method of stabilizing the compound in an aqueous liquid, and a stabilizer of the compound in an aqueous liquid. An aqueous liquid preparation containing the above-mentioned compound and ethylenediaminetetraacetic acid (EDTA) or a salt thereof or a hydrate thereof; a stabilizing method of the compound in an aqueous liquid, including adding the compound and EDTA or a salt thereof or a hydrate thereof to the aqueous liquid; a stabilizer of the above-mentioned compound in an aqueous liquid, which contains EDTA or a salt thereof or a hydrate thereof; and a stabilizer of the compound in an aqueous liquid, which contains EDTA or a salt thereof or a hydrate thereof, and castor oil in combination.Type: ApplicationFiled: December 10, 2015Publication date: February 1, 2018Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Yasuhiro MORI, Masazumi YAMAGUCHI
-
Patent number: 9849121Abstract: An aqueous liquid preparation containing (+)-(S)-4-[4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperidino]butyric acid or a pharmacologically acceptable acid addition salt thereof, which is stabilized with a water-soluble metal chloride, is provided.Type: GrantFiled: October 10, 2014Date of Patent: December 26, 2017Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventor: Masayo Higashiyama
-
Publication number: 20170319665Abstract: The present invention provides a technique for treating retinal epithelium and/or nerves. More specifically, the present invention is an agent for the treatment or prevention of retinal disease or the like and/or a disease, disorder, or ophthalmological state of the nerves, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with retinal pigment epithelial cells and/or nerve cells. Specifically, the present invention can include laminin 411 (?4?1?1), laminin 511 (?5?1?1), laminin 521 (?5?2?1), or fragments of these.Type: ApplicationFiled: October 30, 2015Publication date: November 9, 2017Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20170319693Abstract: The present invention provides a technique for treating the cornea. More specifically, the present invention is an agent for the treatment or prevention of a state of corneal endothelial disease, the agent including at least one factor selected from the group consisting of laminin and fragments thereof, wherein the problem is solved by also providing a technique characterized in that this agent is administered together with corneal endothelial cells. Specifically, the present invention can include laminin 511 (?5?1?1), laminin 521 (?5?2?1), or a fragment of these.Type: ApplicationFiled: October 30, 2015Publication date: November 9, 2017Applicants: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriko KOIZUMI, Naoki OKUMURA, Shigeru KINOSHITA
-
Publication number: 20170191033Abstract: An object of the present invention is to provide a method of inducing pluripotent stem cells to differentiate into clinically applicable retinal ganglion cells. The present invention provides a method for inducing pluripotent stem cells to differentiate into retinal ganglion cells that can be used for clinical application. Such method is a method for producing retinal ganglion cells with elongated axons comprising the following steps: (a) a step of inducing pluripotent stem cells to differentiate into retinal progenitor cells via floating culture; (b) a step of inducing the retinal progenitor cells obtained in step (a) to differentiate into retinal ganglion cells via floating culture; and (c) a step of allowing axons to elongate via adhesion culture of the retinal ganglion cells obtained in step (b).Type: ApplicationFiled: August 7, 2015Publication date: July 6, 2017Applicants: NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT, SENJU PHARMACEUTICAL CO., LTD.Inventors: Noriyuki Azuma, Taku Tanaka, Tadashi Yokoi
-
Patent number: 9617222Abstract: The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.Type: GrantFiled: March 30, 2015Date of Patent: April 11, 2017Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Norihiko Takeda, Tomoyo Miyabe, Shinnosuke Machida, Mamiko Machida, Takeshi Nakajima
-
Patent number: 9616101Abstract: The present invention relates to a differentiation marker and a differentiation controlling technique for an eye cell. More particularly, the present invention has attained an object of providing a differentiation marker for an eye cell among the aforementioned problems, by providing a marker for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, the marker comprising GPR49/LGR5, as well as a detection agent or detection method for identifying a cell having a high proliferation ability among corneal endothelial cells and/or the differentiation ability of a corneal endothelial cell, comprising a substance binding to GPR49/LGR5. In addition, the present invention has attained an object of providing a differentiation controlling technique for an eye cell, by providing an agent for suppressing differentiation and/or promoting proliferation of an eye cell, comprising R-spondins.Type: GrantFiled: July 3, 2013Date of Patent: April 11, 2017Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, THE DOSHISHA, SENJU PHARMACEUTICAL CO., LTD.Inventors: Takahiro Nakamura, Noriko Koizumi, Naoki Okumura, Shigeru Kinoshita, Kana Tominaga, Satoshi Kawasaki
-
Publication number: 20170096400Abstract: The main object of the present invention is to provide a novel compound which has a VEGF receptor tyrosine kinase inhibitory activity and is useful as an active ingredient for the treatment of diseases accompanying angiogenesis or edema, for example, age-related macular degeneration or the like. The present invention includes, for example, an alkynyl indazole derivative represented by the following general formula (I), a pharmaceutical acceptable salt thereof, and a medicine containing thereof.Type: ApplicationFiled: March 30, 2015Publication date: April 6, 2017Applicant: SENJU PHARMACEUTICAL CO., LTD.Inventors: Norihiko TAKEDA, Tomoyo MIYABE, Shinnosuke MACHIDA, Mamiko MACHIDA, Takeshi NAKAJIMA
-
Publication number: 20170043017Abstract: The purpose of the present invention is to provide a polymer gel that can increase drug content ratio and reduce undesirable influence on gel strength and shape stability after the drug release, compared with the conventional techniques. The purpose can be achieved by an anionic drug-containing medical device comprising: (1) an anionic drug; and (2) a copolymer which contains, as constituents, a cationic monomer comprising a condensation product of an alkyl quaternary ammonium compound having a substituted or unsubstituted aralkyl group and (meth)acrylic acid or a salt of the condensation product and a monomer capable of copolymerizing with the condensation product or the salt of the condensation product.Type: ApplicationFiled: April 16, 2015Publication date: February 16, 2017Applicants: SEED CO., LTD., SENJU PHARMACEUTICAL CO., LTD.Inventors: Haruka OBATA, Kiyoshi SHOJI, Yoshiko YAMAZAKI, Toru MATSUNAGA, Takao SATO, Wakiko ASAYAMA, Shinichi YASUEDA
-
Patent number: 9561280Abstract: An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%.Type: GrantFiled: July 8, 2015Date of Patent: February 7, 2017Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shuichi Nishihata, Wakiko Asayama, Suzuka Iemoto
-
Patent number: 9561277Abstract: An aqueous liquid preparation of the present invention containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or its pharmacologically acceptable salt or a hydrate thereof, an alkyl aryl polyether alcohol type polymer such as tyloxapol, or a polyethylene glycol fatty acid ester such as polyethylene glycol monostearate is stable. Since even in the case where a preservative is incorporated into said aqueous liquid preparation, the preservative exhibits a sufficient preservative effect for a long time, said aqueous liquid preparation in the form of an eye drop is useful for the treatment of blepharitis, conjunctivitis, scleritis, and postoperative inflammation. Also, the aqueous liquid preparation of the present invention in the form of a nasal drop is useful for the treatment of allergic rhinitis and inflammatory rhinitis (e.g. chronic rhinitis, hypertrophic rhinitis, nasal polyp, etc.).Type: GrantFiled: September 30, 2014Date of Patent: February 7, 2017Assignee: SENJU PHARMACEUTICAL CO., LTD.Inventors: Shirou Sawa, Shuhei Fujita